


Nothofagin

Cat. No.:	HY-113919		
CAS No.:	11023-94-2		
Molecular Formula:	C ₂₁ H ₂₄ O ₁₀		
Molecular Weight:	436.41		
Target:	Calcium Channel		
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description	Nothofagin, a dihydrochalcone, is isolated from rooibos (<i>Aspalathus linearis</i>) ^[1] . Nothofagin downregulates NF-κB translocation through blocking calcium influx. Nothofagin has antioxidant activity and ameliorates various inflammatory responses such as the septic response and vascular inflammation ^[2] .									
In Vitro	<p>Nothofagin pre-treatment (0.1, 1, 10 μM) decreases the level of histamine release in RBL-2H3 and RPMCs cells. The production of cytokines are downregulated by nothofagin pre-treatment Nothofagin (TNF-α: 1-10 μM; IL-4: 0.1-10 μM, IL-6: 1-10 μM)^[1].</p> <p>Pre-treatment of DNPHSA-stimulated RBL-2H3 with Nothofagin (10 μM) markedly suppresses the phosphorylation of Lyn, Syk, and Akt^[1].</p> <p>Nothofagin (30 μM; for 6 hours) results in inhibited formation of LPS-induced (100 ng/mL; 4 hours) paracellular gaps with the formation of dense F-actin rings in HUVECs^[2].</p> <p>Nothofagin suppresses IgE-mediated mast cell degranulation both in vitro and in vivo^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>Nothofagin (1 mg/kg; orally; once a day; for 7 days) significantly increases the urinary volume of both normotensive (NTR) and spontaneously hypertensive rats (SHR)^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="344 1453 1513 1690"> <tr> <td>Animal Model:</td> <td>Male Wistar normotensive and spontaneously hypertensive rats (3-4 months old) ^[3]</td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Orally; once a day; for 7 days</td> </tr> <tr> <td>Result:</td> <td>Significantly increased the urinary volume of both NTR and SHR.</td> </tr> </table>		Animal Model:	Male Wistar normotensive and spontaneously hypertensive rats (3-4 months old) ^[3]	Dosage:	1 mg/kg	Administration:	Orally; once a day; for 7 days	Result:	Significantly increased the urinary volume of both NTR and SHR.
Animal Model:	Male Wistar normotensive and spontaneously hypertensive rats (3-4 months old) ^[3]									
Dosage:	1 mg/kg									
Administration:	Orally; once a day; for 7 days									
Result:	Significantly increased the urinary volume of both NTR and SHR.									

REFERENCES

- [1]. Wonhwa Lee, et al. Anti-inflammatory Effects of Aspalathin and Nothofagin From Rooibos (*Aspalathus Linearis*) In Vitro and In Vivo. *Inflammation*. 2015 Aug;38(4):1502-16.
- [2]. Byeong-Cheol Kang, et al. Nothofagin Suppresses Mast Cell-Mediated Allergic Inflammation. *Chem Biol Interact*. 2019 Jan 25;298:1-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA